Institutional Ownership
Adaptimmune Therapeutics PLC
CUSIP 00653A107SPONDS ADSADAPYQ1 2026
13D / 13G Filings
31
Schedule 13D/13G on record
Beneficial Filers
12
Distinct reporting persons
Largest Stake
26.6%
Max % of class reported
Institutional Holders
1
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
31 filings · latest Feb 17, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 17, 2026 | Long Focus Capital Management, LLC | 13G | — | — | SEC |
| 2 | Nov 14, 2025 | Two Seas Capital LP | 13G/A | — | 302.0K | SEC |
| 3 | Aug 19, 2025 | New Enterprise Associates 14, L.P. | 13D/A | — | — | SEC |
| 4 | Aug 19, 2025 | Ecor1 Capital, LLC | 13G/A | 4.2% | — | SEC |
| 5 | Aug 13, 2025 | Two Seas Capital LP | 13G/A | 8.5% | — | SEC |
| 6 | May 15, 2025 | Two Seas Capital LP | 13G/A | 8.0% | — | SEC |
| 7 | Feb 14, 2025 | Two Seas Capital LP | 13G | 5.8% | — | SEC |
| 8 | Feb 12, 2025 | Baillie Gifford &Amp; Co | 13G/A | 4.6% | 7091.46T | SEC |
| 9 | Feb 11, 2025 | Long Focus Capital Management, LLC | 13G/A | 8.0% | 20.49M | SEC |
| 10 | Jan 8, 2025 | Matrix Capital Management Company LP | 13G/A | — | 49 | SEC |
21 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Adaptimmune Therapeutics PLC.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Rhumbline Advisers | 3.7K | $72 |